Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | INMT | O95050 | 4/20 | 0.38 |
| ▸ | KDM6A | O15550 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.34 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | TAF1 | P21675 | 1/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100263 | 0.75 | CRBN (0.44) | KDM4ECRBNKDM6AKDM4ACYP2C9 | |
| SCHEMBL25100650 | 0.74 | ALDH1A1 (0.33) | — | |
| Water SCHEMBL6505685 | 0.73 | CRBN (0.43) | KDM4ECRBNKDM6AKDM4ACYP2C9 | |
| Hydrochloric Acid SCHEMBL7524493 | 0.73 | CRBN (0.43) | KDM4ECRBNKDM6AKDM4ACYP2C9 | |
| SCHEMBL10569882 | 0.71 | CRBN (0.41) | KDM4ECRBNKDM6AKDM4ACYP2C9 | |
| SCHEMBL11238862 | 0.67 | CRBN (0.38) | KDM4ECRBNKDM6AKDM4ACYP2C9 | |
| SCHEMBL2211531 | 0.67 | CRBN (0.38) | KDM4ECRBNKDM6AKDM4ACYP2C9 | |
| SCHEMBL7133435 | 0.64 | GSK3A (0.48) | KDM4ECRBNCYP2C9CYP2C19 | |
| SCHEMBL17664675 | 0.62 | RGS4 (0.47) | KDM4E | |
| SCHEMBL23222667 | 0.62 | CRBN (0.37) | KDM4ECRBNKDM6AKDM4ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946415-B2 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946415-B2 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130253194-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-09-26 | — | — | US | disclosed |
| US-20130253194-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253194-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | TPX2, MAP3K1, IRAK1 | KDM4E 2400/4885CRBN 1635/4885APOBEC3A 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.